FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078201731> ?p ?o ?g. }

• W2078201731 endingPage "1534" @default.
• W2078201731 startingPage "1524" @default.
• W2078201731 abstract "ObjectiveMicroenvironmental interactions of malignant B cells can modulate various in vitro physiological responses, including proliferation, migration, apoptosis, and drug resistance. Disease manifestations of human malignant B-cell variants, isolated based on their differential interactions with fibronectin, were examined in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice.Materials and MethodsDisease manifestations were assessed by pathological examinations and skeletal imaging of NOD/SCID mice injected with malignant B-cell variants. Dissemination patterns were analyzed by whole-body real-time imaging of mice injected with fluorescence-labeled malignant cells.ResultsInitial dissemination patterns and dynamics of both high (type A) and low (type F)-adherent variants, following intravenous inoculation, were similar. Both cell types reached the spleen and liver within 30 minutes after injection, then increasingly accumulated within the bone marrow. Mice injected with type-A cells developed multiple myeloma–like disease within the bone marrow, with multiple lytic bone lesions. In contrast, type-F cells displayed low tumorigenic capacity in spite of their efficient homing to the bone marrow niche. In addition, type-A cells grew as extramedullary tumors in some of the intravenous-inoculated mice, and formed solid tumors following subcutaneous injection. Both cell variants retained their characteristics surface markers following in vivo outgrowth as tumors, indicating that at least some of their properties are relatively stable.ConclusionData suggest that the differential tumorigenicity of B-cell adhesive variants is attributable to the capacity of type-A cells to survive and proliferate within the bone marrow, rather than to different initial dissemination of the two cell populations. Microenvironmental interactions of malignant B cells can modulate various in vitro physiological responses, including proliferation, migration, apoptosis, and drug resistance. Disease manifestations of human malignant B-cell variants, isolated based on their differential interactions with fibronectin, were examined in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice. Disease manifestations were assessed by pathological examinations and skeletal imaging of NOD/SCID mice injected with malignant B-cell variants. Dissemination patterns were analyzed by whole-body real-time imaging of mice injected with fluorescence-labeled malignant cells. Initial dissemination patterns and dynamics of both high (type A) and low (type F)-adherent variants, following intravenous inoculation, were similar. Both cell types reached the spleen and liver within 30 minutes after injection, then increasingly accumulated within the bone marrow. Mice injected with type-A cells developed multiple myeloma–like disease within the bone marrow, with multiple lytic bone lesions. In contrast, type-F cells displayed low tumorigenic capacity in spite of their efficient homing to the bone marrow niche. In addition, type-A cells grew as extramedullary tumors in some of the intravenous-inoculated mice, and formed solid tumors following subcutaneous injection. Both cell variants retained their characteristics surface markers following in vivo outgrowth as tumors, indicating that at least some of their properties are relatively stable. Data suggest that the differential tumorigenicity of B-cell adhesive variants is attributable to the capacity of type-A cells to survive and proliferate within the bone marrow, rather than to different initial dissemination of the two cell populations." @default.
• W2078201731 created "2016-06-24" @default.
• W2078201731 creator A5002353248 @default.
• W2078201731 creator A5012223062 @default.
• W2078201731 creator A5029358696 @default.
• W2078201731 creator A5045116114 @default.
• W2078201731 creator A5046264807 @default.
• W2078201731 creator A5071887646 @default.
• W2078201731 date "2008-11-01" @default.
• W2078201731 modified "2023-09-27" @default.
• W2078201731 title "Tumorigenic potential and disease manifestations of malignant B-cell variants differing in their fibronectin adhesiveness" @default.
• W2078201731 cites W1519816848 @default.
• W2078201731 cites W1528621722 @default.
• W2078201731 cites W1528751727 @default.
• W2078201731 cites W1544851750 @default.
• W2078201731 cites W1578954095 @default.
• W2078201731 cites W1750202810 @default.
• W2078201731 cites W1965116261 @default.
• W2078201731 cites W1966207848 @default.
• W2078201731 cites W1974345772 @default.
• W2078201731 cites W1985294292 @default.
• W2078201731 cites W1988603492 @default.
• W2078201731 cites W1991522181 @default.
• W2078201731 cites W2008488333 @default.
• W2078201731 cites W2025490245 @default.
• W2078201731 cites W2026496528 @default.
• W2078201731 cites W2029106419 @default.
• W2078201731 cites W2036488841 @default.
• W2078201731 cites W2039723455 @default.
• W2078201731 cites W2048064990 @default.
• W2078201731 cites W2050273392 @default.
• W2078201731 cites W2059459946 @default.
• W2078201731 cites W2069187469 @default.
• W2078201731 cites W2086790430 @default.
• W2078201731 cites W2104973497 @default.
• W2078201731 cites W2111163979 @default.
• W2078201731 cites W2111836858 @default.
• W2078201731 cites W2156484791 @default.
• W2078201731 cites W2158794607 @default.
• W2078201731 cites W253245484 @default.
• W2078201731 doi "https://doi.org/10.1016/j.exphem.2008.05.009" @default.
• W2078201731 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2975934" @default.
• W2078201731 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18694619" @default.
• W2078201731 hasPublicationYear "2008" @default.
• W2078201731 type Work @default.
• W2078201731 sameAs 2078201731 @default.
• W2078201731 citedByCount "6" @default.
• W2078201731 crossrefType "journal-article" @default.
• W2078201731 hasAuthorship W2078201731A5002353248 @default.
• W2078201731 hasAuthorship W2078201731A5012223062 @default.
• W2078201731 hasAuthorship W2078201731A5029358696 @default.
• W2078201731 hasAuthorship W2078201731A5045116114 @default.
• W2078201731 hasAuthorship W2078201731A5046264807 @default.
• W2078201731 hasAuthorship W2078201731A5071887646 @default.
• W2078201731 hasBestOaLocation W20782017312 @default.
• W2078201731 hasConcept C142724271 @default.
• W2078201731 hasConcept C1491633281 @default.
• W2078201731 hasConcept C150903083 @default.
• W2078201731 hasConcept C151872237 @default.
• W2078201731 hasConcept C189014844 @default.
• W2078201731 hasConcept C18903297 @default.
• W2078201731 hasConcept C203014093 @default.
• W2078201731 hasConcept C207001950 @default.
• W2078201731 hasConcept C2780007613 @default.
• W2078201731 hasConcept C2780931953 @default.
• W2078201731 hasConcept C502942594 @default.
• W2078201731 hasConcept C54355233 @default.
• W2078201731 hasConcept C55851684 @default.
• W2078201731 hasConcept C71924100 @default.
• W2078201731 hasConcept C86492073 @default.
• W2078201731 hasConcept C86803240 @default.
• W2078201731 hasConceptScore W2078201731C142724271 @default.
• W2078201731 hasConceptScore W2078201731C1491633281 @default.
• W2078201731 hasConceptScore W2078201731C150903083 @default.
• W2078201731 hasConceptScore W2078201731C151872237 @default.
• W2078201731 hasConceptScore W2078201731C189014844 @default.
• W2078201731 hasConceptScore W2078201731C18903297 @default.
• W2078201731 hasConceptScore W2078201731C203014093 @default.
• W2078201731 hasConceptScore W2078201731C207001950 @default.
• W2078201731 hasConceptScore W2078201731C2780007613 @default.
• W2078201731 hasConceptScore W2078201731C2780931953 @default.
• W2078201731 hasConceptScore W2078201731C502942594 @default.
• W2078201731 hasConceptScore W2078201731C54355233 @default.
• W2078201731 hasConceptScore W2078201731C55851684 @default.
• W2078201731 hasConceptScore W2078201731C71924100 @default.
• W2078201731 hasConceptScore W2078201731C86492073 @default.
• W2078201731 hasConceptScore W2078201731C86803240 @default.
• W2078201731 hasIssue "11" @default.
• W2078201731 hasLocation W20782017311 @default.
• W2078201731 hasLocation W20782017312 @default.
• W2078201731 hasLocation W20782017313 @default.
• W2078201731 hasLocation W20782017314 @default.
• W2078201731 hasOpenAccess W2078201731 @default.
• W2078201731 hasPrimaryLocation W20782017311 @default.
• W2078201731 hasRelatedWork W1542394131 @default.
• W2078201731 hasRelatedWork W1580944159 @default.
• W2078201731 hasRelatedWork W2000042748 @default.
• W2078201731 hasRelatedWork W2031920810 @default.

• next